Condition: Chronic Pseudomonas Aeruginosa Infection · Cystic Fibrosis · Sponsor: BiomX, Inc.
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| Yale University | New Haven, Connecticut, United States | — |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| Joe DiMaggio Children's Hospital | Hollywood, Florida, United States | — |
| Central Florida Pulmonary Group | Orlando, Florida, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| New York Medical College | Valhalla, New York, United States | — |
| Cincinnati Children's Hospital | Cincinnati, Ohio, United States | — |
| University Hospitals Rainbow Babies and Children's Hospital | Cleveland, Ohio, United States | — |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05010577